Clinical Trial Update: An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients [Phase 3]

View source ↗

Summary

Open-label extension of eculizumab in relapsing neuromyelitis optica shows continuing assessment in a Phase 3 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Status: COMPLETED | Results posted: 2022-08-23